Navigating the DNA Synthesis Landscape
The commercial DNA synthesis market has expanded rapidly, driven by falling per-base costs and growing demand from synthetic biology, cell and gene therapy, and industrial biotechnology. Choosing a synthesis provider is no longer a simple price comparison—factors such as turnaround time, maximum construct length, error rate, biosecurity screening compliance, and downstream cloning services all influence project timelines and outcomes.
How Synthesis Platforms Differ
Two dominant approaches define the market today:
- Silicon-based high-throughput synthesis
- Pioneered by Twist Bioscience, this method miniaturizes chemistry on a silicon chip, enabling the parallel synthesis of thousands of genes at low cost per base. Best suited for large-scale oligo pool orders, variant libraries, and projects requiring high throughput.
- Traditional column-based synthesis
- Used by GenScript, IDT, Eurofins, and most other providers, column synthesis excels at producing longer sequences (up to 20+ kb for some vendors) with high fidelity. Preferred for complex constructs, long genes, and GMP-grade applications.
Key Selection Criteria for Buyers
| Factor | Why It Matters |
|---|---|
| Turnaround time | Express services (4–7 business days) vs. standard (10–15 business days) can impact project milestones significantly |
| Max construct length | Ranges from ~1.8 kb (fragment-based) to 200+ kb (genome-scale assembly) depending on provider |
| Error rate | Industry standard is <1:3,000 bp; some providers guarantee <1:10,000 bp with NGS verification |
| Biosecurity compliance | IGSC members screen orders against pathogen databases—critical for regulated and funded research |
| Downstream services | Cloning into expression vectors, codon optimization, and protein expression services reduce vendor coordination overhead |
Market Context
The global gene synthesis market was valued at approximately $2 billion in 2023 and is projected to grow at a CAGR of ~16%, reaching over $13 billion by 2033. The International Gene Synthesis Consortium (IGSC), founded in 2009, now represents roughly 80% of global gene synthesis capacity and enforces harmonized biosecurity screening protocols across its 40+ member organizations.
Notable recent trends include the shift toward enzymatic DNA synthesis—companies like DNA Script and Ansa Biotechnologies are developing benchtop synthesizers that eliminate chemical reagents—and the growing importance of GMP-grade synthesis to support cell and gene therapy manufacturing pipelines.